3-(2'-乙基-2'-硝基乙烯基)-6-吲哚 | 65283-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(2'-乙基-2'-硝基乙烯基)-6-吲哚
• 英文名称: 3-(2-nitrobut-1-en-1-yl)-1H-indole
• 英文别名: 3-(2'-ethyl-2'-nitrovinyl)-6-indole；3-(2'-ethyl-2'-nitrovinyl)indole；3-(2-nitrobut-1-enyl)-1H-indole
• CAS: 65283-34-3
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: MFTHIYPESIICAN-UHFFFAOYSA-N

物化性质

• 熔点：
  129-132 °C
• 沸点：
  409.7±20.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2'-乙基-2'-硝基乙烯基)-6-吲哚 在 三甲基氯硅烷 、 TEA 、 硼烷 作用下， 以 四氢呋喃 为溶剂， 反应 30.0h， 生成 2,4,6-trichloro-N-[1-(1H-indol-3-ylmethyl)propyl]benzenesulfonamide
  参考文献：
  名称：

  α-甲基色胺磺酰胺衍生物作为新型糖皮质激素受体配体。

  摘要：

  在超高通量筛选（UHTS）活动中，α-甲基色胺磺酰胺被鉴定为人糖皮质激素受体（hGR）配体。将描述潜在的领先活动，包括并行和单点模拟合成以绘制支架图。鉴定出对hGR表现出30 nM结合的配体。将讨论这些化合物的SAR和选择性。

  DOI：

  10.1016/j.bmcl.2006.10.058
• 作为产物：
  描述：

  吲哚 在 ammonium acetate 、 三氯氧磷 作用下， 反应 19.55h， 生成 3-(2'-乙基-2'-硝基乙烯基)-6-吲哚
  参考文献：
  名称：

  Alpha-ethyltryptamines as dual dopamine–serotonin releasers

  摘要：

  The dopamine (DA), serotonin (5-HT), and norepinephrine (NE) transporter releasing activity and serotonin-2A (5-HT2A) receptor agonist activity of a series of substituted tryptamines are reported. Three compounds, 7b, (+)-7d and 7f, were found to be potent dual DA/5-HT releasers and were > 10-fold less potent as NE releasers. Additionally, these compounds had different activity profiles at the 5-HT2A receptor. The unique combination of dual DA/5-HT releasing activity and 5-HT2A receptor activity suggests that these compounds could represent a new class of neurotransmitter releasers with therapeutic potential. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.07.062

文献信息

• [EN] BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION<br/>[FR] DÉRIVÉS BIS-HÉTÉROARYLIQUES EN TANT QUE MODULATEURS DE L'AGRÉGATION DES PROTÉINES
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2017020010A1

  公开（公告）日：2017-02-02

  The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

  本发明涉及某些双杂环芳基化合物，含有它们的药物组合物，以及使用它们的方法，包括用于预防、逆转、减缓或抑制蛋白聚集的方法，以及治疗与蛋白聚集相关的疾病的方法，包括帕金森病、阿尔茨海默病、路易体病、帕金森病伴痴呆、额颞型痴呆、亨廷顿病、肌萎缩侧索硬化和多系统萎缩等神经退行性疾病，以及包括黑色素瘤在内的癌症。
• [EN] AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES D'AZEPINOINDOLE ET DE PYRIDOINDOLE UTILISES COMME AGENTS PHARMACEUTIQUES
  申请人：X CEPTOR THERAPEUTICS INC

  公开号：WO2003099821A1

  公开（公告）日：2003-12-04

  The present invention is directed to compounds of formula (I) and formula (II): formula (I) and (II), wherein R1-R8, A and n are as described in the description. These compounds are used in pharmaceutical compositions and methods for modulating the activity of orphan nuclear receptors.

  本发明涉及化合物的公式（I）和公式（II）：公式（I）和（II），其中R1-R8，A和n如描述中所述。这些化合物用于制备药物组合物，并用于调节孤儿核受体的活性的方法。
• Azepinoindole derivatives as pharmaceutical agents
  申请人：Busch Brett

  公开号：US20050054634A1

  公开（公告）日：2005-03-10

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。具体来说，提供了用于调节受体活性以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱症状的化合物和组合物。
• α-Methyltryptamine sulfonamide derivatives as novel glucocorticoid receptor ligands
  作者：Daniel R. Marshall、Gus Rodriguez、David S. Thomson、Richard Nelson、Allison Capolina

  DOI：10.1016/j.bmcl.2006.10.058

  日期：2007.1

  Alpha-methyltryptamine sulfonamides were identified as human glucocorticoid receptor (hGR) ligands in an ultra high throughput screening (UHTS) campaign. Described will be the hit-to-lead activities, including parallel and single point analog synthesis to map the scaffold. Ligands were identified that exhibited 30 nM binding to hGR. The SAR and selectivity of these compounds will be discussed.

  在超高通量筛选（UHTS）活动中，α-甲基色胺磺酰胺被鉴定为人糖皮质激素受体（hGR）配体。将描述潜在的领先活动，包括并行和单点模拟合成以绘制支架图。鉴定出对hGR表现出30 nM结合的配体。将讨论这些化合物的SAR和选择性。
• Alpha-ethyltryptamines as dual dopamine–serotonin releasers
  作者：Bruce E. Blough、Antonio Landavazo、John S. Partilla、Ann M. Decker、Kevin M. Page、Michael H. Baumann、Richard B. Rothman

  DOI：10.1016/j.bmcl.2014.07.062

  日期：2014.10

  The dopamine (DA), serotonin (5-HT), and norepinephrine (NE) transporter releasing activity and serotonin-2A (5-HT2A) receptor agonist activity of a series of substituted tryptamines are reported. Three compounds, 7b, (+)-7d and 7f, were found to be potent dual DA/5-HT releasers and were > 10-fold less potent as NE releasers. Additionally, these compounds had different activity profiles at the 5-HT2A receptor. The unique combination of dual DA/5-HT releasing activity and 5-HT2A receptor activity suggests that these compounds could represent a new class of neurotransmitter releasers with therapeutic potential. (C) 2014 Elsevier Ltd. All rights reserved.